Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HY-PHEN vs AMMONIUM CHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
HY-PHEN is a combination of hydrocodone (a mu-opioid receptor agonist) and acetaminophen (an analgesic and antipyretic). Hydrocodone binds to mu-opioid receptors in the CNS, altering pain perception and emotional response to pain. Acetaminophen inhibits cyclooxygenase (COX) enzymes, particularly in the CNS, reducing prostaglandin synthesis.
Ammonium chloride is an acidifying agent. It dissociates to ammonium and chloride ions. The ammonium ion is converted to urea in the liver, releasing hydrogen ions, which lower blood and urinary p H. It also increases chloride concentration, promoting excretion of bicarbonate and other bases.
Management of moderate to moderately severe pain,Off-label: Acute pain, postoperative pain, chronic pain (limited use due to acetaminophen toxicity risk)
Treatment of metabolic alkalosis,Urinary acidification to enhance excretion of weak bases in poisoning,Expectorant (off-label)
1-2 tablets (acetaminophen 500 mg/hydrocodone 5-10 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
For metabolic alkalosis: 1-2 g orally 3-4 times daily; or 1 g (as 2 mmol/kg) intravenously over 4-6 hours, repeat as needed based on blood gas analysis.
2-3 hours (terminal elimination half-life). Clinical context: Short half-life requires frequent dosing (every 4-6 hours) for sustained analgesic effect.
Terminal elimination half-life is approximately 8-12 hours in normal renal function; prolonged in renal impairment (up to 30 hours) due to reliance on renal acid excretion.
Hydrocodone is metabolized via CYP3A4 to hydromorphone (active) and via CYP2D6 to norhydrocodone. Acetaminophen is primarily metabolized via glucuronidation and sulfation; a minor pathway via CYP2E1 produces a hepatotoxic metabolite (NAPQI) that is normally detoxified by glutathione.
Ammonium chloride is metabolized in the liver via the urea cycle, where ammonium is converted to urea, consuming bicarbonate and generating hydrogen ions.
Renal (primarily as glucuronide conjugates and unchanged drug). Approximately 90-95% eliminated in urine within 24 hours; fecal excretion <5%.
Renal: >99% as ammonium ion (NH4+) and chloride (Cl-), with acid excretion via conversion of NH4+ to urea in liver; minimal biliary/fecal.
25-35% bound to plasma proteins (mainly albumin).
<10% bound to plasma proteins (primarily albumin).
0.9-1.5 L/kg. Clinical meaning: Moderate Vd indicates distribution into total body water; does not extensively accumulate in tissues.
Approximately 0.3-0.5 L/kg, distributing mainly in extracellular fluid; minimal intracellular penetration.
Oral: 60-90% (first-pass metabolism reduces systemic availability); Rectal: 70-80%; IV/IM: 100%.
Oral: 70-80% (subject to first-pass hepatic conversion of NH4+ to urea); intravenous: 100%.
GFR 30-50 m L/min: administer at 75% of usual dose every 6 hours; GFR <30 m L/min: administer at 50% of usual dose every 8 hours. Avoid in severe renal impairment.
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-60 m L/min: reduce dose by 50% and monitor for acidosis. For GFR >60 m L/min: no adjustment necessary.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and extend interval to every 8 hours; Class C: contraindicated.
No specific Child-Pugh dose adjustments; use with caution in severe hepatic impairment due to risk of encephalopathy.
Not recommended for children under 18 years due to risk of opioid-related adverse effects; alternative analgesics preferred.
For metabolic alkalosis: 50-100 mg/kg orally every 6-8 hours, not to exceed 6 g/day. Intravenous: 2-3 mmol/kg over 4-6 hours, repeat based on blood p H.
Initiate with lowest effective dose (e.g., acetaminophen 500 mg/hydrocodone 5 mg) every 6 hours; monitor for respiratory depression, constipation, and falls; may require dose reduction by 25-50% compared to younger adults.
Start at low end of dosing range; monitor renal function and electrolytes closely due to age-related decline in GFR.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen (especially in children) can cause hepatotoxicity; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risks from concomitant use with benzodiazepines or other CNS depressants (additive respiratory depression).
None.
Hepatotoxicity due to acetaminophen (dose-dependent); respiratory depression (especially in elderly, debilitated, or COPD); opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; seizures; serotonin syndrome with serotonergic drugs; urinary retention; bile duct spasm; use in patients with head injury or increased intracranial pressure (risk of masking neurological signs); neonatal withdrawal syndrome.
May cause metabolic acidosis, hyperammonemia in hepatic impairment, and electrolyte disturbances. Use with caution in patients with renal or hepatic disease, pulmonary insufficiency, or cardiac edema.
Significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction (e.g., paralytic ileus); severe hepatic impairment; hypersensitivity to hydrocodone, acetaminophen, or any component; use of MAO inhibitors within 14 days (hypertensive crisis).
Severe hepatic or renal impairment, primary respiratory acidosis, and patients with uremia or high serum bicarbonate levels.
Avoid alcohol consumption due to increased risk of hepatotoxicity and CNS depression. Grapefruit juice may inhibit CYP2D6 metabolism of hydrocodone, potentially altering analgesic effect; avoid concurrent use. High-fat meals may increase absorption of hydrocodone; take consistently with or without food.
Avoid excessive consumption of alkaline foods (e.g., dairy products, fruits) as they may counteract the acidifying effect. Maintain a consistent diet to avoid fluctuations in acid-base balance.
Pregnancy Category C. First trimester: No well-controlled studies; potential for fetal harm based on animal studies (cleft palate, skeletal anomalies). Second and third trimesters: Prolonged use may cause neonatal withdrawal syndrome (irritability, hypertonia, respiratory depression) if used near term. Avoid use in pregnancy unless benefit outweighs risk.
Ammonium chloride is not associated with major human teratogenicity. However, due to its potential to induce metabolic acidosis, high doses may pose theoretical fetal risks, including fetal acidosis and altered fetal p H homeostasis, particularly in the second and third trimesters. No specific trimester-specific risks are well-documented.
HY-PHEN (hydrocodone/acetaminophen) is excreted into breast milk in low concentrations. M/P ratio for hydrocodone is approximately 2.0, for acetaminophen ~1.0. Use caution; monitor infant for sedation, respiratory depression, and poor feeding. Consider risk of neonatal withdrawal if maternal use is chronic.
Ammonium chloride is excreted into breast milk in small amounts. The M/P ratio is not well-established. At therapeutic doses, exposure to the nursing infant is likely low and not expected to cause adverse effects. Caution is advised with high doses due to potential for maternal acidosis and subsequent infant effects. Consider monitoring infant for signs of acidosis if maternal therapy is prolonged or high-dose.
No specific dose adjustments established for pregnancy. Increased plasma volume and enhanced hepatic metabolism in pregnancy may reduce drug concentrations, potentially requiring higher doses to achieve analgesic effect. However, avoid high doses due to risk of acetaminophen hepatotoxicity and fetal opioid exposure. Use lowest effective dose for shortest duration.
Pregnancy increases plasma volume and renal clearance, which may reduce the effectiveness of ammonium chloride as an acidifying agent. Higher doses may be required to achieve therapeutic effect, but this must be balanced against the risk of acidosis. No standard dose-adjustment guidelines exist; dosing should be individualized based on maternal acid-base monitoring. Avoid excessive doses that could cause severe acidosis.
HY-PHEN is a combination of hydrocodone and acetaminophen. Monitor for acetaminophen hepatotoxicity; maximum daily acetaminophen dose should not exceed 4 g from all sources. Hydrocodone is a prodrug metabolized by CYP2D6 to hydromorphone; poor metabolizers may have reduced analgesia while ultra-rapid metabolizers risk toxicity. Avoid concurrent use with other CNS depressants including alcohol due to additive respiratory depression. Taper dose when discontinuing after prolonged use to prevent withdrawal.
Ammonium chloride is used as a systemic acidifying agent to treat metabolic alkalosis. Monitor serum electrolytes and acid-base status closely during therapy. Avoid in severe hepatic or renal impairment. Use with caution in patients with respiratory acidosis.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not take other products containing acetaminophen (e.g., Tylenol, cold medicines) while using this medication to avoid liver damage.,Avoid alcohol completely while taking this drug; it increases the risk of liver damage and severe drowsiness.,Do not drive or operate heavy machinery until you know how this medication affects you; it may cause dizziness or drowsiness.,Store securely away from children and others; misuse can cause addiction, overdose, or death.,Do not stop taking suddenly after long-term use; your doctor will help you taper off to prevent withdrawal symptoms.
Take this medication exactly as prescribed. Do not exceed the recommended dose.,Notify your doctor if you experience nausea, vomiting, confusion, or rapid breathing.,Avoid taking with antacids or alkalinizing agents as they may reduce effectiveness.,Stay hydrated unless otherwise directed by your physician.,Inform your healthcare provider of all medications you are taking, especially diuretics or corticosteroids.
No interactions on record
"Ammonium chloride, an acidifying agent, reduces urinary pH, which increases the renal clearance of lisdexamfetamine and its active metabolite d-amphetamine. This accelerated elimination leads to decreased systemic exposure and potentially diminished therapeutic efficacy of lisdexamfetamine. Clinically, patients may experience reduced symptom control for ADHD or binge eating disorder, requiring dose adjustments or alternative therapies."
"Sufentanil, a potent opioid analgesic, may increase renal excretion of ammonium chloride by promoting diuresis through opioid-induced release of antidiuretic hormone (ADH) and subsequent water reabsorption, leading to dilutional acidosis and enhanced ammonium excretion. This interaction can result in reduced serum ammonium levels and decreased efficacy of ammonium chloride as an acidifying agent, potentially compromising its therapeutic effect in metabolic alkalosis or urinary tract infections. Clinical outcomes may include incomplete correction of metabolic alkalosis or reduced antimicrobial activity of ammonium chloride in the urine."
"Ammonium chloride acidifies the urine, which increases the renal excretion of amphetamine by favoring its ionized form in the tubular lumen, thereby reducing its reabsorption. This leads to a decreased serum concentration of amphetamine and potentially diminished therapeutic efficacy. Clinically, patients may experience reduced mood-elevating or stimulant effects, requiring dose adjustment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HY-PHEN vs AMMONIUM CHLORIDE, answered by our medical review team.
HY-PHEN is a Opioid Antitussive Combination that works by HY-PHEN is a combination of hydrocodone (a mu-opioid receptor agonist) and acetaminophen (an analgesic and antipyretic). Hydrocodone binds to mu-opioid receptors in the CNS, altering pain perception and emotional response to pain. Acetaminophen inhibits cyclooxygenase (COX) enzymes, particularly in the CNS, reducing prostaglandin synthesis.. AMMONIUM CHLORIDE is a Expectorant/Systemic Acidifier that works by Ammonium chloride is an acidifying agent. It dissociates to ammonium and chloride ions. The ammonium ion is converted to urea in the liver, releasing hydrogen ions, which lower blood and urinary p H. It also increases chloride concentration, promoting excretion of bicarbonate and other bases.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HY-PHEN and AMMONIUM CHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HY-PHEN is: 1-2 tablets (acetaminophen 500 mg/hydrocodone 5-10 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. The standard adult dose of AMMONIUM CHLORIDE is: For metabolic alkalosis: 1-2 g orally 3-4 times daily; or 1 g (as 2 mmol/kg) intravenously over 4-6 hours, repeat as needed based on blood gas analysis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HY-PHEN and AMMONIUM CHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HY-PHEN is classified as Category C. Pregnancy Category C. First trimester: No well-controlled studies; potential for fetal harm based on animal studies (cleft palate, skeletal anomalies). Second and third trimesters:. AMMONIUM CHLORIDE is classified as Category C. Ammonium chloride is not associated with major human teratogenicity. However, due to its potential to induce metabolic acidosis, high doses may pose theoretical fetal risks, includ. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.